Phone: +263 (242) 741 308/9
Pharma Strategies | Zimbabwe, Zambia, South Africa
  • Home
  • About Us
  • Our Work
  • Product Launches
  • News
  • Media
  • Links
  • Contact
  • Search
  • Menu
Novartis News

New long term social impact and sustainability targets

New long term social impact and sustainability targets
metzgma4
Fri, 04/10/2026 – 10:52

Read more about New long term social impact and sustainability targets

  • Print
  • PDF
April 10, 2026/by metzgma4
https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png 0 0 metzgma4 https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png metzgma42026-04-10 10:52:222026-04-10 10:52:22New long term social impact and sustainability targets
Novartis News

New long term social impact and sustainability targets

New long term social impact and sustainability targets
metzgma4
Fri, 04/10/2026 – 10:52

Read more about New long term social impact and sustainability targets

  • Print
  • PDF
April 10, 2026/by metzgma4
https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png 0 0 metzgma4 https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png metzgma42026-04-10 10:52:222026-04-10 10:52:22New long term social impact and sustainability targets
Novartis News

New long term social impact and sustainability targets

New long term social impact and sustainability targets
metzgma4
Fri, 04/10/2026 – 10:52

Read more about New long term social impact and sustainability targets

  • Print
  • PDF
April 10, 2026/by metzgma4
https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png 0 0 metzgma4 https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png metzgma42026-04-10 10:52:222026-04-10 10:52:22New long term social impact and sustainability targets

PRODUCTS

  • UperioDecember 17, 2019 - 4:56 pm
  • TasignaDecember 2, 2019 - 2:40 pm
  • GalvusDecember 2, 2019 - 2:19 pm
  • AfinitorDecember 2, 2019 - 2:09 pm

TAGS

Blood Pressure Cancer Novartis Osteoarthritis Read more about A cancer patient gets a new lease on life Read more about A legacy of blood cancer innovation Read more about A partnership against epilepsy Read more about Empowering the next generation of healthcare leaders Read more about FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade Read more about Going upstream to improve heart health in Philadelphia Read more about How Novartis is helping to eliminate leprosy Read more about Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease Read more about Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions Read more about New long term social impact and sustainability targets Read more about New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline Read more about New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline Read more about Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation Read more about Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies Read more about Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer Read more about Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa Read more about Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2 Read more about Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline Read more about Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben Read more about Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA Read more about Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials Read more about Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G) Read more about Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer Read more about Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan Read more about Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial  Read more about Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria Read more about Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance Read more about Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU) Read more about Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH Read more about Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer Read more about Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML Read more about Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML Read more about Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH Read more about Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd. Read more about Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025 Read more about Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day Read more about Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy Read more about Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab Read more about Violence against innocent people runs counter to our work to improve human health Read more about Water project revives rural community in India Rheumatoid Arthritis

MENU

  • Home
  • About Us
  • Our Work
  • Product Launches
  • News
  • Media
  • Links
  • Contact

Calendar

April 2026
M T W T F S S
« Mar    
 12345
6789101112
13141516171819
20212223242526
27282930  

NOVARTIS NEWS

  • New long term social impact and sustainability targetsApril 10, 2026 - 10:52 am

ADDRESS

Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe

CALL US

+263 (242) 741 308
+263 (242) 741 309
Mon-Fri: 8am – 5pm

Privacy Policy

Gallery

  • UperioDecember 17, 2019 - 4:56 pm
  • TasignaDecember 2, 2019 - 2:40 pm
© Copyright - Pharma Strategies | Zimbabwe
Scroll to top